While hitting the top of the charts is an excellent achievement, losing that spot on a technicality has to be gutting. Read more about it here.

I reiterate a BUY rating with a $52/share price target, expecting double-digit returns as growth drivers materialize. Read more here.

Endexx is accelerating its operational scaling efforts, with a clear focus on expanding its wellness portfolio. This expansion is being driven primarily through its subsidiaries, CBD Unlimited and ...

Fiscal year 2025/2026 Precision Medicine for type 1 diabetes Fully enrolled registrational Phase 3 program Diamyd Medical develops a proprietary ...

U.S.–Israel–GCC strategy, Hormuz risk, oil shock, global supply chain impact and escalation analysis. As of March 27, 2026—one month after the February 28 assassination of Supreme Leader Ayatollah Ali ...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with commen ...